FDA Grants U.S. Approval of Ziihera® (Zanidatamab-Hrii) for the Treatment of Adults With Previously Treated, Unresectable or Metastatic Her2-Positive (Ihc 3+) Biliary Tract Cancer (BTC)
FDA批准Ziihera®（Zanidatamab-Hrii）用於治療曾接受治療的不可切除或轉移性Her2陽性（Ihc 3+）膽道癌（BTC）成人患者。
